Atossa Therapeutics (ATOS) Accumulated Expenses (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Accumulated Expenses of $235000.0 for Q1 2026, down 34.9% year-over-year from $361000.0 in Q1 2025, and up 10.33% quarter-over-quarter from $213000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Accumulated Expenses (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Accumulated Expenses for 16 consecutive years, with $235000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 34.9% year-over-year to $235000.0; the TTM figure through Mar 2026 stood at $235000.0 (down 34.9% YoY), while the FY2025 annual figure was $213000.0, down 83.68% from the prior year.
- Accumulated Expenses improved to $235000.0 in Q1 2026 per ATOS's latest filing, from $213000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.6 million in Q1 2024 and bottomed at $131000.0 in Q2 2024.
- Historically, Accumulated Expenses has averaged $588647.1 across 5 years, with a median of $504000.0 in 2022.
- Annual changes were most pronounced in 2024 — Accumulated Expenses soared 553.04% — and 2025, when it slumped 83.68%.
- Atossa Therapeutics' Accumulated Expenses stood at $1.1 million in 2022, then slumped by 77.71% to $236000.0 in 2023, then jumped by 452.97% to $1.3 million in 2024, then plunged by 83.68% to $213000.0 in 2025, then climbed by 10.33% to $235000.0 in 2026.
- Business Quant data shows ATOS's Accumulated Expenses at $235000.0 in Q1 2026, $213000.0 in Q4 2025, and $771000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.38 Mn |
| Mar 31, 2026 | 235,000.00 |
| Dec 31, 2025 | 213,000.00 |
| Sep 30, 2025 | 771,000.00 |
| Jun 30, 2025 | 615,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 748,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 236,000.00 |
| Sep 30, 2023 | 806,000.00 |
| Jun 30, 2023 | 716,000.00 |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 206,000.00 |
| Jun 30, 2022 | 504,000.00 |
| Mar 31, 2022 | 241,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | 107,846.00 |